| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics
|
Aug 11, 2026 | HOLD |
Strong Buy
+119.7% avg upside
21 analysts
|
$17.00
52.46% Upside
|
+0.0% | · |
|
TYRA
Tyra Bioscience
|
Aug 11, 2026 | BUY |
Strong Buy
+76.0% avg upside
17 analysts
|
$39.00
55.21% Upside
|
· | · |
|
LYEL
Lyell Immunopharma
|
Aug 11, 2026 | SELL |
Strong Buy
+94.5% avg upside
12 analysts
|
$12.00
15.14% Downside
|
+1.1% | · |
|
BBIO
BridgeBio Pharma
|
Aug 11, 2026 | BUY |
Strong Buy
+12.8% avg upside
34 analysts
|
$104.00
24.35% Upside
|
+0.0% | · |
|
RCUS
Arcus Biosciences
|
Aug 11, 2026 | HOLD |
Strong Buy
+23.2% avg upside
20 analysts
|
$29.00
0.51% Upside
|
-0.6% | · |
|
INSM
Insmed
|
Aug 07, 2026 | BUY |
Strong Buy
+33.7% avg upside
37 analysts
|
$214.00
61.90% Upside
|
-1.7% | · |
|
LGND
Ligand Pharma
|
Aug 07, 2026 | BUY |
Strong Buy
-6.6% avg upside
15 analysts
|
— | -1.4% | · |
|
CYTK
Cytokinetics
|
Aug 06, 2026 | HOLD |
Strong Buy
+17.8% avg upside
36 analysts
|
$85.00
12.36% Upside
|
-7.5% | · |
|
BMRN
BioMarin Pharmaceutical
|
Aug 06, 2026 | BUY |
Strong Buy
+35.2% avg upside
52 analysts
|
$86.00
22.48% Upside
|
+14.3% | · |
|
TVTX
Travere Therapeutics
|
Aug 05, 2026 | BUY |
Strong Buy
-8.9% avg upside
22 analysts
|
$71.00
14.51% Upside
|
-0.6% | · |
|
SNDX
Syndax Pharmaceuticals
|
Aug 05, 2026 | BUY |
Strong Buy
+75.4% avg upside
27 analysts
|
$26.00
31.58% Upside
|
-2.2% | · |
|
RCKT
Rocket Pharmaceuticals
|
Aug 03, 2026 | BUY |
Buy
+384.4% avg upside
29 analysts
|
$10.00
193.16% Upside
|
+5.9% | · |
|
MDGL
Madrigal Pharmaceuticals
|
Jul 30, 2026 | HOLD |
Strong Buy
-6.4% avg upside
33 analysts
|
$543.00
1.17% Upside
|
+8.7% | · |
|
BIIB
Biogen
|
Jul 29, 2026 | HOLD |
Strong Buy
+21.4% avg upside
52 analysts
|
$219.00
5.10% Upside
|
-0.2% | · |
|
KURA
Kura Oncology
|
Jul 27, 2026 | BUY |
Strong Buy
+161.3% avg upside
26 analysts
|
$30.00
205.75% Upside
|
-1.6% | · |
|
IKT
Inhibikase Therapeutics
|
Jul 27, 2026 | BUY |
Strong Buy
+148.2% avg upside
8 analysts
|
$6.00
149.06% Upside
|
+2.1% | · |
|
ABOS
Acumen Pharmaceuticals
|
Jun 11, 2026 | BUY |
Strong Buy
+222.9% avg upside
10 analysts
|
$8.00
219.92% Upside
|
+4.2% | · |
|
EIKN
Eikon Therapeutics, Inc.
|
Jun 03, 2026 | BUY |
Buy
+129.2% avg upside
5 analysts
|
$32.00
207.74% Upside
|
-1.5% | · |
|
HOWL
Werewolf Therapeutics
|
Feb 17, 2026 | BUY |
Strong Buy
+1706.1% avg upside
8 analysts
|
$7.00
1738.18% Upside
|
-40.9% | · |
|
OKUR
OnKure Therapeutics
|
Mar 28, 2024 | SELL |
Buy
+499.2% avg upside
13 analysts
|
$12.00
205.38% Upside
|
+73.1% | · |
|
KLRS
Kalaris Therapeutics
|
Dec 26, 2023 | SELL |
Buy
+220.0% avg upside
13 analysts
|
$1.00
74.88% Downside
|
+37.0% | · |
|
QTTB
Q32 Bio
|
Nov 17, 2023 | HOLD |
Buy
+288.0% avg upside
24 analysts
|
— | +226.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.